CDX
Detroit 562
Tumor indication
Pharyngeal
Tumor subtype
Pharyngeal carcinoma
Description
Detroit 562 (Pharyngeal Cancer CDX Model)
The Detroit 562 cell line was derived from a metastatic pharyngeal carcinoma. It is classified as a head and neck squamous cell carcinoma (HNSCC) model. Detroit 562 is widely used in studies of upper aerodigestive tract cancers. Its reproducible biology makes it valuable for evaluating therapies in HNSCC.
Key Features:
- Derived from pharyngeal squamous cell carcinoma.
- Represents HNSCC biology.
- Maintains epithelial morphology.
- Consistent tumorigenicity in xenografts.
Applications:
Detroit 562 is applied in testing novel therapies for HNSCC. It supports biomarker discovery and evaluation of EGFR-targeted agents. Researchers use it to study mechanisms of tumor progression in head and neck cancers. Its reproducibility makes it useful in preclinical oncology pipelines.
Details
- Tumor indication
- Pharyngeal
- Tumor subtype
- Pharyngeal carcinoma
- Organism
- Human
- Mouse sex
- Female
Mutated genes
Select a gene to see the variants recorded for this line.
Gene expression
Show all values
| Gene | Expression |
|---|
Expression measured across the Champions panel.
Request this cell line
Let's build the right study, together.
Backed by deep expertise in these models, our team will work with you to design the study around your target, line of therapy, and endpoint.